Allergan has secured approval from the US Food and Drug Administration (FDA) for its Natrelle Inspira cohesive breast implants.
The new gummy implants, which combine high gel fill ratio and cohesive gel, will provide women with a new breast shaping option.
Natrelle Inspira cohesive breast implants are available in both smooth and Biocell textured surfaces.
The new breast implants are developed for breast augmentation of women with at least 22 years old.
It includes primary breast augmentation to increase breast size and revision surgery to correct or improve the result of a primary breast augmentation surgery.
The implants will also be used for breast reconstruction, which includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality.
In February 2015, the company received FDA approval for Natrella Inspira round gel-filled breast implants with responsive gel.
Allergan chief R&D officer David Nicholson said: “Natrelle Inspira cohesive breast implants are just the latest example of our commitment to innovation in breast aesthetics and plastic surgery, and we are proud that we are able to continue to offer advancements in technology that allow physicians and their patients more options.
“Natrelle Inspira cohesive allows patients to get the same high gel fill ratio and fullness offered by the Natrelle Inspira line of implants, with our highly cohesive, form-stable gel.”